Release of clonal block in B cell chronic lymphocytic leukaemia by engagement of co-operative epitopes on CD40

Απλή σελίδα τεκμηρίου
dc.contributor.authorJacob, A.en
dc.contributor.authorPound, J. D.en
dc.contributor.authorChalla, A.en
dc.contributor.authorGordon, J.en
dc.date.accessioned2015-11-24T18:54:27Z
dc.date.available2015-11-24T18:54:27Z
dc.identifier.issn0145-2126-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/18685
dc.rightsDefault Licence-
dc.subjectAntibodies, Monoclonal/pharmacologyen
dc.subjectAntigens, CD40/*immunology/metabolismen
dc.subjectB-Lymphocytes/cytology/drug effects/immunologyen
dc.subjectCD40 Liganden
dc.subjectCell Cycleen
dc.subjectClone Cells/cytology/drug effects/immunologyen
dc.subjectDNA/biosynthesis/drug effectsen
dc.subjectDrug Synergismen
dc.subjectEpitopes/*immunologyen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectInterleukin-4/pharmacologyen
dc.subjectLeukemia, Lymphocytic, Chronic, B-Cell/*immunology/*pathologyen
dc.subjectLigandsen
dc.subjectMaleen
dc.subjectMembrane Glycoproteins/pharmacologyen
dc.subjectRecombinant Proteins/pharmacologyen
dc.subjectSolubilityen
dc.titleRelease of clonal block in B cell chronic lymphocytic leukaemia by engagement of co-operative epitopes on CD40en
heal.abstractThe clonal cells of patients with B-chronic lymphocytic leukaemia (B-CLL)--which essentially reside in a resting configuration--are characterised by a relative refractoriness to the normal signals for B cell growth and differentiation. Previously it has been shown that, using an in vitro culture system where CD40 is hyper-crosslinked by monoclonal antibody (mAb) held on CD32-transfected mouse L cells, the clonal block in B-CLL cells can be released with a resultant high rate of DNA synthesis ensuing. In the present study, we report that such release can be achieved purely with soluble reagents whereby co-operative epitopes on CD40 are targeted by the combined use of mAb and soluble recombinant CD40L. Substantial levels of DNA synthesis were induced under such conditions in 7/18 patients using CD40-targeted reagents alone and in 16/18 patients in the additional presence of interleukin 4. Possible extrapolation of these findings to novel therapeutic modalities could be envisaged.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/9669843-
heal.journalNameLeuk Resen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate1998-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ